Irozorb S 5 Injection contains Elemental Iron at a concentration of 20 mg/ml and is indicated for the treatment and prevention of iron deficiency anemia when oral iron therapy is inadequate or contraindicated. This parenteral iron preparation facilitates rapid replenishment of iron stores by providing bioavailable elemental iron directly into the bloodstream, bypassing gastrointestinal absorption limitations. Irozorb S 5 Injection is particularly useful in patients with chronic kidney disease, malabsorption syndromes, or those undergoing hemodialysis who require efficient correction of iron deficiency. The formulation is administered intravenously under strict medical supervision, with dosage individualized based on the patient’s hemoglobin levels, iron stores, and clinical response. Adverse reactions may include hypersensitivity, hypotension, nausea, and injection site reactions; therefore, monitoring during and after administration is essential. Contraindications include known hypersensitivity to the product or its components, iron overload conditions, and anemia not caused by iron deficiency. Irozorb S 5 Injection should be used cautiously in patients with active infections or hepatic impairment. Proper administration and adherence to recommended dosing protocols ensure optimal therapeutic outcomes while minimizing potential risks associated with intravenous iron therapy.